BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Core Insights - BriaCell Therapeutics Corp. has added UCLA Health Jonsson Comprehensive Cancer Center to its pivotal Phase 3 clinical study evaluating Bria-IMT™ in combination with a checkpoint inhibitor for advanced metastatic breast cancer [1][2] - The Phase 3 study aims to improve survival outcomes in patients with metastatic breast cancer, with overall survival as the primary endpoint [2] - The Bria-IMT combination regimen has received FDA Fast Track designation, indicating its potential to address significant unmet medical needs [2] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [4] - The company is currently conducting a pivotal Phase 3 study (Bria-ABC, NCT06072612) to evaluate the effectiveness of its treatment in a multi-center clinical setting [1][3] Clinical Study Details - The Phase 3 study will conduct an interim analysis after 144 patient events (deaths) have occurred [2] - The study design builds on positive survival data from a previous Phase 2 study, which was presented at ASCO 2025 [2] - The inclusion of UCLA Health is part of BriaCell's strategy to partner with top-tier institutions to enhance trial enrollment and execution [2]